已收盤 11-20 16:00:00 美东时间
-0.220
-6.92%
GT Biopharma ( ($GTBP) ) just unveiled an update. On November 11, 2026, GT Biop...
11-12 22:53
GT Biopharma presented new preclinical data at the SITC 2026 Annual Meeting, showing that combining GTB-5550, a B7-H3-targeted TriKE NK cell engager, with a KRAS inhibitor enhances NK cell cytotoxicity against pancreatic tumor cells. The combination improved tumor control, reduced metastasis, and increased NK cell infiltration in PDAC models. GT Biopharma is exploring a future Phase 1b study to evaluate this combination in pancreatic cancer patie...
11-09 12:00
GT Biopharma, Inc. has been selected for an oral presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. The presentation, titled "Inhibition of the KRAS oncoprotein sensitizes pancreatic cancer to NK cell immunotherapy," will be delivered by Paarth Dodhiawala on November 6, 2026. The session focuses on combination therapies involving cell therapy to enhance treatment effectiveness in solid tumors. GT Biopharma's TriKE...
10-26 12:00
GT Biopharma Files Prospectus Related To The Offer Up To 13,502,835 Shares Of Common Stock By Selling Stockholders
10-10 05:32
GT Biopharma ( ($GTBP) ) has provided an announcement. GT Biopharma, Inc., a Na...
09-26 04:54
GT Biopharma ( ($GTBP) ) has issued an update. On September 14, 2026, GT Biopha...
09-15 21:18
GT Biopharma will host a webinar on September 11, 2026, to discuss its TriKE® platform for cancer treatment. Michael Breen, CEO, and Dr. Jeffrey Miller will cover clinical progress in blood cancers and solid tumors, dose level insights, platform positioning, and future milestones. The webinar, titled "The TriKE® Platform, Clinical Progress, and the Case for NK Cell Immunotherapy," starts at 2:00 p.m. Eastern Time. Registration is available via th...
09-11 12:00
GT Biopharma ( ($GTBP) ) just unveiled an update. On September 2, 2026, GT Biop...
09-04 00:20
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.08) by 50 percent. This is a 78.18 percent increase over losses of $(0.55) per share from the same period last year.
08-14 20:29
GT Biopharma press release (GTBP): Q2 net loss for the second quarter of 2026 of approximately $4.5 million, compared to $30.2 million for the same comparable quarter of 2025. The Company had cash and...
08-14 20:10